

Amendments to the Claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1 (Currently amended). An immunizing composition, comprising an immunizing effective amount of an antigenic product which induces an immune response against an epitope that spans the β -secretase cleavage site of amyloid precursor protein (A β PP) so as to inhibit cleavage of A β PP by β -secretase, and a pharmaceutically acceptable carrier, diluent, excipient, adjuvant, or auxiliary agent, ~~wherein said antigenic product comprises a display vehicle and an antigenic peptide displayed on said display vehicle, said antigenic peptide comprising a 6-14 amino acid residue A β PP epitope that spans the β -secretase cleavage site of A β PP.~~

2 (Currently amended). The immunizing composition of claim ~~1~~52, wherein said display vehicle comprises a dendritic polymer, built on a core molecule, which is at least difunctional so as to provide branching, and containing up to 16 terminal functional groups to which said antigenic peptide is joined by covalent bonds.

3 (Original). The immunizing composition of claim 2, wherein said dendritic polymer contains eight terminal functional groups to which an antigenic peptide is joined.

4 (Previously Presented). The immunizing composition of claim 2, wherein said antigenic peptide comprises residues 1 to 8 of SEQ ID NO:1.

5 (Previously Presented). The immunizing composition of claim 2, wherein said antigenic peptide comprises the amino acid sequence of SEQ ID NO:5.

6 (Currently amended). The immunizing composition of claim 2, wherein said antigenic peptide comprises two overlapping A β PP epitopes ~~of said~~ that both span the β -secretase cleavage site of A β PP.

7 (Original). The immunizing composition of claim 6, wherein said two overlapping A β PP epitopes are identical.

8 (Original). The immunizing composition of claim 2, wherein said core molecule is lysine.

9 (Original). The immunizing composition of claim 2, further comprising a molecule having adjuvant properties joined to said dendritic polymer.

10 (Currently amended). The immunizing composition of claim ~~2~~ 1, wherein said antigenic product is encapsulated in a liposome.

11 (Currently amended). The immunizing composition of claim ~~4~~ 52, wherein said display vehicle comprises a viral display vehicle displaying on its surface said antigenic peptide.

12 (Original). The immunizing composition of claim 11, wherein said viral display vehicle is a filamentous bacteriophage.

13 (Previously Presented). The immunizing composition of claim 11, wherein said antigenic peptide comprises residues 1 to 8 of SEQ ID NO:1.

14 (Previously Presented). The immunizing composition of claim 11, wherein said antigenic peptide comprises the amino acid sequence of SEQ ID NO:5.

15 (Currently Amended). A method for inducing an immune response against the β -secretase cleavage site of A β PP, comprising administering the immunizing composition of claim 1 to a human subject in need thereof to induce an immune response against the β -secretase cleavage site of A β PP and ~~block~~inhibit β -secretase cleavage of A β PP, thereby inhibiting the formation of amyloid β .

Claims 16-26 (Cancelled).

27 (Currently Amended). The immunizing composition of claim ~~25~~1, wherein said antigenic peptide consists of residues 1 to 8 of SEQ ID NO:1.

Claim 28 (Cancelled).

29 (Currently Amended). The immunizing composition of claim ~~25~~1, wherein said antigenic peptide consists of the amino acid sequence of SEQ ID NO:5.

Claims 30-41 (Cancelled).

42 (Previously Presented). The immunizing composition of claim 4, wherein the residue at position 6 of SEQ ID NO:1 is Met.

43 (Previously Presented). The immunizing composition of claim 4, wherein the residue at position 6 of SEQ ID NO:1 is Leu.

44 (Previously Presented). An antigenic peptide consisting of 6-14 amino acid residues of the amyloid precursor protein (A β PP) that span the β -secretase cleavage site of A β PP.

45 (Previously Presented). The antigenic peptide of claim 44, wherein said antigenic peptide comprises residues 1 to 8 of SEQ ID NO:1.

46 (Previously Presented). The antigenic peptide of claim 45, wherein the residue at position 6 of SEQ ID NO:1 is Met.

47 (Previously Presented). The antigenic peptide of claim 45, wherein the residue at position 6 of SEQ ID NO:1 is Leu.

48 (Previously Presented). The antigenic peptide of claim 44, wherein said antigenic peptide consists of 1 to 8 of SEQ ID NO:1.

49 (Previously Presented). The antigenic peptide of claim 44, wherein said antigenic peptide comprises the amino acid sequence of SEQ ID NO:5.

50 (Previously Presented). The antigenic peptide of claim 44, wherein said antigenic peptide consists of the amino acid sequence of SEQ ID NO:5.

51(New). The immunizing composition of claim 1, wherein said antigenic product comprises an antigenic peptide comprising an A β PP epitope that spans the β -secretase cleavage site of A β PP.

52(New). The immunizing composition of claim 1, wherein said antigenic product comprises a display vehicle and an antigenic peptide displayed on said display vehicle, said antigenic peptide comprising an A β PP epitope that spans the β -secretase cleavage site of A β PP.

53 (New). The immunizing composition of claim 51, wherein said antigenic peptide comprises residues 1 to 8 of SEQ ID NO:1.

54(New). The immunizing composition of claim 53, wherein the residue at position 6 of SEQ ID NO:1 is Met.

55(New). The immunizing composition of claim 53, wherein the residue at position 6 of SEQ ID NO:1 is Leu.

56 (New). The immunizing composition of claim 51, wherein said antigenic peptide comprises the amino acid sequence of SEQ ID NO:5.

57 (New). The immunizing composition of claim 51, wherein said antigenic peptide comprises two overlapping A β PP epitopes that both span the β -secretase cleavage site of A β PP.

58 (New). The immunizing composition of claim 57, wherein said two overlapping A β PP epitopes are identical.